Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission. Printed by #UserName#, #Company_Name#


Printed By

UsernamePublicRestriction

Lloydspharmacy owner expects further branch closures across Europe

Lloydspharmacy’s parent company expects to close more branches “across Europe”, it has revealed.

US company McKesson, which owns Lloydspharmacy, referred to “expected further closures of retail pharmacy stores across Europe”, in slides to accompany its 2018-19 financial results, published yesterday (May 8).

When asked by C+D whether this means more Lloydspharmacies will close in the UK, McKesson said it had “no further details to add at this time”.

Closures have formed a key part of Lloydspharmacy’s recent business strategy. In 2017 it announced plans to stop trading in around 190 “commercially unviable” branches, in an effort to cope with the funding cuts in England.

C+D has since identified 78 of these branches that Lloydspharmacy has closed, and another 104 that it sold.

“Accelerating UK restructuring”

Discussing the financial results, McKesson executive vice president and chief financial officer Britt Vitalone also referred to “further closures of retail pharmacy stores…throughout Europe”, and said the business is “working to reinforce and accelerate our UK restructuring”.

McKesson is “focused on executing against key initiatives to strengthen the business in the UK”, he added.

Mr Vitalone predicted “low to mid-single digit percent revenue growth” in Europe for 2020, but added that this “assumes a modest improvement in our UK business”, with no additional funding cuts.

Expanding on his comments, McKesson president and chief operating officer Brian Tyler said “rationalising” its Lloydspharmacy portfolio and “restructuring operations” has “given us the confidence we can get Europe back to a modest growth next year”.

Adjusted operating profit for McKesson’s European pharmaceutical solutions division – which includes Lloydspharmacy – in the first three months of 2019 was $23 million (£17.7m), a 72% drop on the same period the previous year.

Have any pharmacies closed in your area recently?

Related Content

Topics

Pre-reg Trainee

Tonbridge, Kent

 Salary: £22,000

Apply Now
UsernamePublicRestriction

Register

CD005882

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel